Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Deloitte
UBS
US Department of Justice
Queensland Health
McKinsey
Moodys
QuintilesIMS
Fuji
Chinese Patent Office

Generated: October 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,037,525

« Back to Dashboard

Which drugs does patent 7,037,525 protect, and when does it expire?


Patent 7,037,525 protects TRILEPTAL and is included in two NDAs. There have been two Paragraph IV challenges on Trileptal.

Protection for TRILEPTAL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-three patent family members in thirty-three countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: 7,037,525

Title:Oxacarbazepine film-coated tablets
Abstract:The invention relates to formulations, e.g. film-coated tablets containing oxcarbazepine and to processes for the production of said formulations. The film-coated tablets have a tablet core comprising a therapeutically effective dose of oxacarbazepine being in a finely ground form having a mean particle size of from 4 to 12 .mu.m (median value), and a hydrophilic permeable outer coating.
Inventor(s): Schlutermann; Burkhard (Au, DE)
Assignee: Novartis AG (Basel, CH)
Application Number:10/429,634
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis
TRILEPTAL
oxcarbazepine
TABLET;ORAL021014-001Jan 14, 2000ABRXYesNo► Subscribe► SubscribeY
Novartis
TRILEPTAL
oxcarbazepine
TABLET;ORAL021014-002Jan 14, 2000ABRXYesNo► Subscribe► SubscribeY
Novartis
TRILEPTAL
oxcarbazepine
TABLET;ORAL021014-003Jan 14, 2000ABRXYesYes► Subscribe► SubscribeY
Novartis
TRILEPTAL
oxcarbazepine
SUSPENSION;ORAL021285-001May 25, 2001ABRXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,037,525

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Switzerland97/331Feb 14, 1997

International Patent Family for Patent: 7,037,525

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2277791► Subscribe
China1247471► Subscribe
China1170542► Subscribe
China1626093► Subscribe
Colombia4920215► Subscribe
Cyprus2480► Subscribe
Czech Republic9902879► Subscribe
Czech Republic298840► Subscribe
Germany69814367► Subscribe
Denmark0966287► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Covington
Harvard Business School
Chubb
Deloitte
Medtronic
Boehringer Ingelheim
Daiichi Sankyo
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot